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AbstR Act
This systematic review and meta-analysis of randomized con-
trolled trials (RCTs) was conducted to clarify the effect of mel-
atonin supplementation on glycemic control. Databases includ-
ing PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane 
Central Register of Controlled Trials were searched until July 
30th, 2018. Two reviewers independently assessed study eli-
gibility, extracted data, and evaluated the risk of bias for includ-
ed trials. Heterogeneity among included studies was assessed 
using Cochran’s Q test and I-square (I2) statistic. Data were 
pooled using random-effect models and mean difference (MD) 
was considered as the overall effect size. Twelve trials out of 
292 selected reports were identified eligible to be included in 
current meta-analysis. The pooled findings indicated that me-
latonin supplementation significantly reduced  fasting glucose 
(MD = –6.34; 95 % CI, –12.28, –0.40; p = 0.04; I2: 65.0) and in-
creased the quantitative insulin sensitivity check index (QUICKI) 
(MD = 0.01; 95 % CI, 0.00, 0.02; p = 0.01; I2: 0.0). However, me-
latonin administration did not significantly influence insulin 
levels (MD = –1.03; 95 % CI, –3.82, 1.77; p = 0.47; I2: 0.53), 
homeostasis model assessment of insulin resistance (HOMA-IR) 
(MD = –0.34; 95 % CI, –1.25, 0.58; p = 0.37; I2: 0.37) or HbA1c 
levels (MD = –0.22; 95 % CI, –0.47, 0.03; p = 0.08; I2: 0.0). In 
summary, the current meta-analysis showed a promising effect 
of melatonin supplementation on glycemic control through 
reducing fasting glucose and increasing QUICKI, yet additional 
prospective studies are recommended, using higher supple-
mentation doses and longer intervention period, to confirm 
the impact of melatonin on insulin levels, HOMA-IR and HbA1c.
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Abbreviations
CHD Coronary heart disease
FPG Fasting plasma glucose
HbA1c Hemoglobin A1c
HOMA-IR  Homeostasis model of assessment-estimated insulin 
resistance
NASH Nonalcoholic steatohepatitis
QUICKI Quantitative insulin-sensitivity check index
T2DM Type 2 diabetes mellitus
Introduction
Diabetes mellitus is a chronic, life-threatening metabolic disorder, 
which is or will soon became a massive economic burden for many 
communities [1]. The global prevalence of diabetes among adults 
(aged 20–79 years) was 6.4 % in 2010, affecting 285 million adults. 
Unfortunately, this will increase to 7.7 %, involving 439 million adults, 
by 2030. Between 2010 and 2030, there will be a 69 % increase in the 
number of adults suffering from diabetes in developing countries and 
a 20 % increase in developed countries [1]. Type 2 diabetes mellitus 
(T2DM) has been significantly associated with the development of mi-
crovascular and macrovascular complications [2–4]. Studies have also 
shown that T2DM is associated with increased oxidative stress occur-
ring as a consequence of hyperglycemia, hyperinsulinemia, increased 
insulin resistance, reduced insulin sensitivity, and dyslipidemia [5–8].
Melatonin is an endogenous indole amine, secreted by the pin-
eal gland, which facilitates physiologic timings based on circadian 
patterns [9]. Previously, the beneficial effects of melatonin on met-
abolic profiles and inhibitory actions on adrenocorticotropic hor-
mone responses were documented [10–13]. In addition, animal 
studies and non-randomized human trials have proposed the pos-
sible impact of melatonin administration on improving glycemic 
control, insulin resistance, hypertension, and dyslipidemia [14, 15]. 
Melatonin intake has been shown to regulate blood glucose levels 
through its ability to bind directly to melatonin receptors on hepat-
ocytes [16] and regulate the uptake of glucose in adipocytes, by 
modulating the expression of the glucose uptake transporter [17]. 
Moreover, melatonin has been reported to stimulate the secretion 
of glucagon, another hormone that is important in glucose and in-
sulin metabolism [18]. However, few randomized controlled trials 
(RCTs) have evaluated the effects of melatonin on glycemic con-
trol, and the published findings are inconsistent. In a study con-
ducted by Rezvanfar et al. [19], melatonin administration at a dos-
age of 6 mg for 12 weeks decreased fasting glucose in diabetic pa-
tients. The same research group has recently found that melatonin 
administration at a dosage of 10 mg/day for 12 weeks improved 
glycemic control in diabetic patients suffering from coronary heart 
disease (CHD) [20]. Moreover, a 12-week trial using melatonin 
showed significant improved insulin sensitivity and the inflamma-
tory status in obese patients with Acanthosis Nigricans [21]. There 
are, however, results as well that, for example, 5 mg/day melatonin 
supplementation for 2 months did not affect fasting glucose in pa-
tients diagnosed with metabolic syndrome (MetS) [15]. Differenc-
es in study design, study population characteristics, the dosage of 
melatonin used, and the duration of intervention might explain the 
discrepancies among the findings published to date.
To the best of our knowledge, there is no systematic review or 
meta-analyses of RCTs determining the effect of melatonin supple-
mentation on glycemic control. Thus, the present meta-analysis 
was summarized available publications demonstrating an effect of 
melatonin supplementation on glycemic control and examined the 
impact of melatonin on glycemic control using meta-analysis.
Materials and Methods
Search and studies selection strategies
The scientific international databases, including Cochrane Library, 
EMBASE, PubMed, and Web of Science were searched for relevant 
studies published until July 30th, 2018. A search strategy was de-
veloped using the following MeSH and text keywords; intervention 
(“melatonin” AND “supplementation” OR “intake”), and outcomes 
[“fasting glucose” OR “FPG” OR “insulin” OR “homeostasis model 
assessment of insulin resistance (HOMA-IR)” OR “HbA1c” OR 
“quantitative insulin sensitivity check index (QUICKI)].
Inclusion and exclusion criteria
RCTs with the following criteria were included in meta-analysis: human 
trial with either parallel or cross-over design, data for the effect of me-
latonin on glycemic control extracted from RCTs (including mean 
changes of glucose, insulin, HOMA-IR, HbA1c, and QUICKI with stand-
ard deviations (SDs) and related 95 % confidence intervals (CIs) for the 
both intervention and placebo groups). Other studies such as animal 
experiments, in vitro studies, case reports, observational studies, in-
vestigations without control group, and studies that did not achieve 
the least quality score were excluded from this meta-analysis.
Data extraction and quality assessment
Two independent authors (VO and NM) screened the retrieved 
 articles based on the eligibility criteria. In the first step the title and 
abstract of studies were reviewed. Then, the full-text of relevant 
studies was retrieved and assessed to ascertain the suitability of a 
study for the meta-analysis. Any disagreement was resolved through 
the judgment of the third author (ZA).
The following data were extracted from selected studies: the first 
authors’ name, year of publication, study location, age, study design, 
sample size, dose of intervention, duration of study, type of disease, 
the mean and standard deviation (SD) for fasting glucose, insulin, 
HOMA-IR, HbA1c, and QUICKI in each intervention group. The qual-
ity of the selected RCTs was assessed by same independent authors 
using the Cochrane Collaboration risk of bias tool based on the fol-
lowing criteria: “randomization generation, allocation concealment, 
blinding of participants and outcome assessors, incomplete outcome 
data, and selective outcome reporting, and other sources of bias”.
Data synthesis and statistical analysis
The effects of melatonin supplementation on the changes of the follow-
ing outcomes were calculated: 1) fasting glucose, 2) insulin, 3) HOMA-IR, 
4) HbA1c, and 5) QUICKI. The mean differences (MDs) with 95 % CI were 
used for pooling data to determine effect sizes. The change score ap-
proach was used to calculate the effect size of melatonin supplementa-
tion on the identified outcome. The random-effect model was used to 
report the pooled effect sizes using 95 % confidence interval (CI).
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Heterogeneity and publication bias
Heterogeneity across included studies was assessed using 
Cochran’s Q test (with significant p-value lower than 0.1) and 
I-square test (I2 greater than 50 percent showing significant heter-
ogeneity). The funnel plot, as well as the Beggs’s and Egger’s re-
gression tests were used to determine the publication bias. Both 
STATA 11.0 (Stata Corp., College Station, TX, USA) and Review Man-
ager 5.3 (Cochrane Collaboration, Oxford, UK) were applied for data 
analysis.
Results
The step by step flowchart for identification and selection is illus-
trated in ▶Fig. 1. Finally, 12 RCTs out of 292 articles were selected to 
be included in meta-analysis. Ten trials had measured the effects 
of melatonin on fasting glucose, 4 on insulin, 3 on HOMA-IR, 3 on 
HbA1c and 2 on QUICKI. The sample size of included RCTs in this 
meta-analysis varied from 20 to 128 participants. Duration of in-
tervention ranged from 30 days to 24 weeks. Selected RCTs were 
published between 2005 and 2018. Dosage of melatonin supple-
ments varied from 3 to 10 mg/day. The detailed characteristics of 
selected RCTs are summarized in ▶table 1.
Main outcomes
Forest plots reporting the effect sizes of primary RCTs on glycemic 
control parameters are indicated in ▶Fig. 2 1–5. The pooled find-
ings using random-effect models indicated that melatonin supple-
mentation significantly reduced fasting glucose (MD = –6.34; 95 % 
CI, –12.28, –0.40; p = 0.04; I2: 65.0) and increased QUICKI (MD = 
0.01; 95 % CI, 0.00, 0.02; p = 0.01; I2: 0.0). However, melatonin ad-
ministration did not influence insulin levels (MD = –1.03; 95 % CI, 
–3.82, 1.77; p = 0.47; I2: 0.53), HOMA-IR (MD = –0.34; 95 % CI, –1.25, 
0.58; p = 0.37; I2: 0.37) and HbA1c (MD = –0.22; 95 % CI, –0.47, 0.03; 
p = 0.08; I2: 0.0).
▶Fig. 1 Literature search and review flowchart for selection of studies.
Articles screened by title and
abstract (n = 125)
Full text articles assessed for
eligibility (n = 24)
Studies included in this study
(n = 12)
Articles excluded (n = 167) due to duplicate
articles, not randomized controlled trials,
review and not human
Excluded non-relevant articles (n = 81)
Articles excluded (n = 12):
1. Data presentation inappropriate for meta-
analysis (n = 9)
2. Not placebo (n = 3)
Articles identified through
electronic database search (n = 292)
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▶Fig 2 1–5: Meta-analysis lipid profiles mean differences estimates for 1 fasting glucose, 2 for insulin, 3 for homeostasis model assessment of 
insulin resistance, 4 for HbA1c, 5 and for quantitative insulin sensitivity check index in melatonin and placebo groups.
787
D
ow
nl
oa
de
d 
by
: K
as
ha
n 
Un
ive
rs
ity
 o
f M
ed
ica
l S
cie
nc
es
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Doosti-Irani A et al. Melatonin Supplementation and Glycemic Control … Horm Metab Res 2018; 50: 783–790
Review
Publication bias
Funnel plots demonstrating publication bias are illustrated in ▶Fig 3. 
Results of Begg’s (p = 0.02) and Egger’s (p = 0.008) tests for the effe-
cts of melatonin supplementation on fasting glucose were statisti-
cally significant.
Discussion
To our best knowledge, this is the first meta-analysis of RCTs eval-
uating the effect of melatonin supplementation on glycemic con-
trol. The current meta-analysis showed the beneficial impact of 
melatonin supplementation on glycemic control including a signif-
icant reduction in fasting glucose and an increase in QUICKI, though 
melatonin did not affect insulin levels, HOMA-IR, and HbA1c.
Existing evidence are promising regarding the impact of mela-
tonin on glycemic control. In healthy individuals, glucose homeo-
stasis is tightly controlled via a complex pathway of regulatory 
mechanisms involving multiple organs and tissues. Normal glucose 
balance is usually impaired due to a sustained reduction in both 
pancreatic beta-cell function and insulin secretion [22]. In animal 
models, melatonin has been shown to regulate circulating serum 
glucose levels through its ability to bind directly to melatonin re-
ceptors on hepatocytes [16] as well as to regulate the uptake of 
glucose by adipocytes, through modulating the expression of the 
glucose uptake transporter [17]. Abnormal nocturnal melatonin 
profiles have been reported in diabetic patients, especially for those 
suffering from diabetic neuropathy [23]. Low melatonin secretion 
has also been independently correlated with a higher risk of devel-
oping T2DM; an association that further establishes the roles of 
melatonin in glycemic control and insulin sensitivity [24]. There is 
a new evidence suggesting a relationship between melatonin pro-
duction disturbances and impairment of insulin, glucose and lipid 
metabolism [25]; and antioxidant capacity [26]. Results from both 
in vivo and in vitro studies have shown that in patients diagnosed 
with MetS, night-time melatonin level is significantly correlated to 
nighttime insulin concentrations [27]. Moreover, melatonin stim-
ulates the secretion of glucagon, which is the second hormone im-
portant in glucose metabolism [18]. In a meta-analysis, we have 
previously reported that melatonin significantly decreased inflam-
matory markers including CRP and IL-6, but not TNF-α levels in pa-
tients with MetS and related disorders [28]. However, some of the 
RCTs that assessed the effects of melatonin supplementation on 
glycemic control have yielded inconsistent results. Rezvanfar et al. 
[19] found that melatonin administration at a dosage of 6 mg to 
type 2 diabetic patients for 12 weeks decreased fasting glucose lev-
els. In addition, combined myo-inositol and melatonin supplemen-
tation for 6 months significantly improved glucose metabolism 
among women experiencing the menopausal transition [29]. More-
over, a 12-week supplementation of melatonin improved insulin 
sensitivity and the inflammatory status of obese patients with 
Acanthosis Nigricans [21]. Controversial findings also exist; as an 
example, 5 mg/day melatonin supplementation for 2 months did 
not affect fasting glucose levels in patients with MetS [15]. Differ-
ences in study design, study population characteristics, the dosage 
of melatonin used and the duration of intervention might explain 
the discrepancies among existing evidence.
Melatonin receptors (MT1 and MT2) are present in both animal 
[30, 31] and human [32] pancreatic islets. In addition, an increase 
in the expression of MT1 and MT2 receptors is reported in the pan-
creas of diabetic rats and in subjects with T2DM [33]. Associations 
between single nucleotide polymorphisms situated close to (or 
within) the gene encoding MT2 (MTNR1B), and an increased risk of 
developing T2DM [34], diminished B-cell function [35] and im-
paired glycemic control [36] have been reported in different co-
horts from a variety of different ethnicities. The inhibitory effects 
of melatonin intake on elevated fasting glucose may be mediated 
through the function of 2 G-protein-coupled receptors. These re-
ceptors are expressed in both the beta cells of the pancreatic islets 
and the adipocytes, playing important roles in the regulation of 
blood glucose [37].
This meta-analysis has some limitations. There were few eligible 
RCTs including a modest number of participants. Various doses of 
melatonin were administered for intervention in the included stud-
ies. The results of publication bias were statistically significant for 
the effects of melatonin supplementation on FPG. Thus, additional 
RCTs are required to obtain the necessary pooled effect size. In ad-
dition, due to low number of RCTs included for the effect of mela-
tonin supplementation on insulin, HOMA-IR, HbA1c and QUICKI, we 
could not assess the publication bias for these outcomes.
Conclusions
In summary, the current meta-analysis showed a potentially ben-
eficial of melatonin supplementation on improving glycemic con-
trol through reducing fasting glucose and increasing QUICKI. How-
ever, additional prospective studies are recommended using higher 
supplementation doses and longer intervention period to deter-
mine the impact of melatonin on insulin levels, HOMA-IR, and 
HbA1c.
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Notice
Please note: This article was changed according to the Erratum 
on November 14th 2018.
Erratum
1.  In the article, the name of the co-author was given 
 incorrectly. The correct name of the author is  
Mohammad Ali Mansournia.
2.  In the abstract section the correct abbreviation of  
“mean difference” is MD.
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